Drugs / Adze1.C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07086105 | Oct 2025 → Oct 2027 expected | metastatic melanoma | Adze Biotechnology Australia Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adze1.C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07086105 ↗ |
| Route | Other | “administered by intratumoural injection” NCT07086105 ↗ |